Upcoming Dividend • Jul 21
Upcoming dividend of NT$0.80 per share Eligible shareholders must have bought the stock before 28 July 2026. Payment date: 31 August 2026. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 3.9%. Lower than top quartile of Taiwanese dividend payers (5.1%). Higher than average of industry peers (3.1%). Reported Earnings • May 18
First quarter 2026 earnings released: EPS: NT$0.29 (vs NT$1.22 in 1Q 2025) First quarter 2026 results: EPS: NT$0.29 (down from NT$1.22 in 1Q 2025). Revenue: NT$233.6m (down 12% from 1Q 2025). Net income: NT$90.2m (down 77% from 1Q 2025). Profit margin: 39% (down from 146% in 1Q 2025). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 17
Full year 2025 earnings released: EPS: NT$1.72 (vs NT$0.57 in FY 2024) Full year 2025 results: EPS: NT$1.72 (up from NT$0.57 in FY 2024). Revenue: NT$1.20b (down 1.3% from FY 2024). Net income: NT$537.4m (up 195% from FY 2024). Profit margin: 45% (up from 15% in FY 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Mar 11
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to NT$20.80, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 16x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 11% over the past three years. Tillkännagivande • Mar 06
Savior Lifetec Corporation, Annual General Meeting, Jun 17, 2026 Savior Lifetec Corporation, Annual General Meeting, Jun 17, 2026. Location: 2 floor no,26, nan k`o 3rd rd., tainan city Taiwan New Risk • Nov 24
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. Cash payout ratio: 154% Dividend yield: 2.3% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (20% accrual ratio). Minor Risk Dividend is not well covered by cash flows (154% cash payout ratio). Reported Earnings • Nov 16
Third quarter 2025 earnings released: EPS: NT$0.26 (vs NT$0.14 in 3Q 2024) Third quarter 2025 results: EPS: NT$0.26 (up from NT$0.14 in 3Q 2024). Revenue: NT$282.5m (down 15% from 3Q 2024). Net income: NT$79.9m (up 87% from 3Q 2024). Profit margin: 28% (up from 13% in 3Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 15
Second quarter 2025 earnings released: NT$0.05 loss per share (vs NT$0.069 profit in 2Q 2024) Second quarter 2025 results: NT$0.05 loss per share (down from NT$0.069 profit in 2Q 2024). Revenue: NT$335.5m (down 3.8% from 2Q 2024). Net loss: NT$16.9m (down 177% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Declared Dividend • Jun 28
Dividend increased to NT$0.41 Dividend of NT$0.41 is 381% higher than last year. Ex-date: 14th July 2025 Payment date: 5th August 2025 Dividend yield will be 2.1%, which is higher than the industry average of 1.6%. Payout Ratios Payout ratio: 15%. Cash payout ratio: 10%. New Risk • May 31
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 108% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company. Reported Earnings • May 17
First quarter 2025 earnings released: EPS: NT$1.22 (vs NT$0.22 in 1Q 2024) First quarter 2025 results: EPS: NT$1.22 (up from NT$0.22 in 1Q 2024). Revenue: NT$263.9m (up 1.8% from 1Q 2024). Net income: NT$386.1m (up 443% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Apr 25
Savior Lifetec Corporation to Report Q1, 2025 Results on May 02, 2025 Savior Lifetec Corporation announced that they will report Q1, 2025 results on May 02, 2025 Tillkännagivande • Apr 11
Savior Lifetec Corporation Obtains Approval for Marketing in China and Obtains Drug License Savior Lifetec Corporation obtained approval for marketing in China and obtained drug license. SLC's generic drug Ertapenem Sodium for Injection has been approved for drug registration by the NMPA of China, and a drug registration certificate has been obtained. This product is a carbapenem used for the treatment of complicated infections caused by multidrug-resistant bacteria. Indications of the product include: Complicated intra-abdominal infection, Community-acquired pneumonia, Acute pelvic infection, Complicated urinary tract infection, and Complicated skin and soft tissue infection. This product is the first to receive a drug registration certificate in the China market for the Company. Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to NT$15.90, the stock trades at a trailing P/E ratio of 27.7x. Average trailing P/E is 16x in the Pharmaceuticals industry in Taiwan. Total loss to shareholders of 12% over the past three years. New Risk • Apr 06
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company. Reported Earnings • Mar 30
Full year 2024 earnings released: EPS: NT$0.57 (vs NT$0.095 in FY 2023) Full year 2024 results: EPS: NT$0.57 (up from NT$0.095 in FY 2023). Revenue: NT$1.22b (up 16% from FY 2023). Net income: NT$182.4m (up NT$152.4m from FY 2023). Profit margin: 15% (up from 2.9% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Mar 07
Savior Lifetec Corporation, Annual General Meeting, Jun 13, 2025 Savior Lifetec Corporation, Annual General Meeting, Jun 13, 2025. Location: 2 floor no,26, nan k`o 3rd rd., tainan city Taiwan Tillkännagivande • Feb 27
Savior Lifetec Corporation to Report Fiscal Year 2024 Results on Mar 06, 2025 Savior Lifetec Corporation announced that they will report fiscal year 2024 results on Mar 06, 2025 Buy Or Sell Opportunity • Feb 11
Now 21% undervalued The stock has been flat over the last 90 days, currently trading at NT$20.65. The fair value is estimated to be NT$26.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last 3 years. Meanwhile, the company has become profitable. Buy Or Sell Opportunity • Jan 10
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 4.4% to NT$20.65. The fair value is estimated to be NT$26.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last 3 years. Meanwhile, the company has become profitable. Reported Earnings • Nov 18
Third quarter 2024 earnings released: EPS: NT$0.13 (vs NT$0.052 loss in 3Q 2023) Third quarter 2024 results: EPS: NT$0.13 (up from NT$0.052 loss in 3Q 2023). Revenue: NT$332.5m (up 16% from 3Q 2023). Net income: NT$42.7m (up NT$59.2m from 3Q 2023). Profit margin: 13% (up from net loss in 3Q 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 17
Second quarter 2024 earnings released: EPS: NT$0.07 (vs NT$0.016 in 2Q 2023) Second quarter 2024 results: EPS: NT$0.07 (up from NT$0.016 in 2Q 2023). Revenue: NT$348.7m (up 56% from 2Q 2023). Net income: NT$21.9m (up 335% from 2Q 2023). Profit margin: 6.3% (up from 2.3% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has remained flat. Tillkännagivande • Aug 01
Savior Lifetec Corporation to Report Q2, 2024 Results on Aug 08, 2024 Savior Lifetec Corporation announced that they will report Q2, 2024 results on Aug 08, 2024 Buy Or Sell Opportunity • Jul 09
Now 25% undervalued Over the last 90 days, the stock has risen 7.8% to NT$23.45. The fair value is estimated to be NT$31.29, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 26% over the last 3 years. Earnings per share has declined by 38%. Declared Dividend • Jun 28
Dividend reduced to NT$0.085 Dividend of NT$0.085 is 18% lower than last year. Ex-date: 12th July 2024 Payment date: 5th August 2024 Dividend yield will be 0.3%, which is lower than the industry average of 1.6%. Payout Ratios Payout ratio: 26%. Cash payout ratio: 6%. Tillkännagivande • Jun 27
Savior Lifetec Corporation Approves the Cash Dividend, Payable on August 05, 2024 Savior Lifetec Corporation at its shareholders’ meeting held on June 26, 2024, approved the cash dividend of TWD 0.0851 per share will be distributed, totaling TWD 27,027,002. Ex-rights (Ex-dividend) date: July 12, 2024. Ex-rights (Ex-dividend) record date: July 20, 2024. Payment date of cash dividend distribution: August 05, 2024. Reported Earnings • May 19
First quarter 2024 earnings released: EPS: NT$0.22 (vs NT$0.011 loss in 1Q 2023) First quarter 2024 results: EPS: NT$0.22 (up from NT$0.011 loss in 1Q 2023). Revenue: NT$259.2m (up 17% from 1Q 2023). Net income: NT$71.1m (up NT$74.6m from 1Q 2023). Profit margin: 27% (up from net loss in 1Q 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Tillkännagivande • Apr 28
Savior Lifetec Corporation to Report Q1, 2024 Results on May 03, 2024 Savior Lifetec Corporation announced that they will report Q1, 2024 results at 9:00 AM, Taipei Standard Time on May 03, 2024 New Risk • Mar 26
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 23% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company. Reported Earnings • Mar 21
Full year 2023 earnings released: EPS: NT$0.09 (vs NT$0.12 in FY 2022) Full year 2023 results: EPS: NT$0.09 (down from NT$0.12 in FY 2022). Revenue: NT$1.05b (down 17% from FY 2022). Net income: NT$30.0m (down 18% from FY 2022). Profit margin: 2.9% (in line with FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance. Tillkännagivande • Mar 09
Savior Lifetec Corporation, Annual General Meeting, Jun 14, 2024 Savior Lifetec Corporation, Annual General Meeting, Jun 14, 2024. Location: 2F., No. 26, Nanke 3rd Rd., Xinshi Dist., Tainan City Taiwan Agenda: To consider 2023 Business Report; to consider 2023 distributable compensation for employees and directors; to consider 2023 Annual Earnings Cash Dividend Distribution Report; to consider Audit Committee’s Review Report; to consider 2023 Business Report and Financial Statements; to consider Company's 2023 earnings distribution; and to consider Lifting the non-competition restriction case of the company’s directors. Reported Earnings • Nov 11
Third quarter 2023 earnings released: NT$0.05 loss per share (vs NT$0.42 profit in 3Q 2022) Third quarter 2023 results: NT$0.05 loss per share (down from NT$0.42 profit in 3Q 2022). Revenue: NT$287.2m (down 18% from 3Q 2022). Net loss: NT$16.5m (down 112% from profit in 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance. New Risk • Nov 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Nov 06
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to NT$21.35, the stock trades at a trailing P/E ratio of 71.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in Taiwan. Total loss to shareholders of 32% over the past three years. Reported Earnings • Aug 05
Second quarter 2023 earnings released: EPS: NT$0.02 (vs NT$0.005 loss in 2Q 2022) Second quarter 2023 results: EPS: NT$0.02 (up from NT$0.005 loss in 2Q 2022). Revenue: NT$223.2m (down 37% from 2Q 2022). Net income: NT$5.03m (up NT$6.56m from 2Q 2022). Profit margin: 2.3% (up from net loss in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Jun 29
Upcoming dividend of NT$0.10 per share at 0.5% yield Eligible shareholders must have bought the stock before 06 July 2023. Payment date: 03 August 2023. Trailing yield: 0.5%. Lower than top quartile of Taiwanese dividend payers (5.5%). Lower than average of industry peers (1.6%). Reported Earnings • Mar 16
Full year 2022 earnings released: EPS: NT$0.11 (vs NT$0.031 in FY 2021) Full year 2022 results: EPS: NT$0.11 (up from NT$0.031 in FY 2021). Revenue: NT$1.27b (down 27% from FY 2021). Net income: NT$36.4m (up 266% from FY 2021). Profit margin: 2.9% (up from 0.6% in FY 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Reported Earnings • Nov 16
Third quarter 2022 earnings released: EPS: NT$0.42 (vs NT$0.18 loss in 3Q 2021) Third quarter 2022 results: EPS: NT$0.42 (up from NT$0.18 loss in 3Q 2021). Revenue: NT$348.1m (down 8.2% from 3Q 2021). Net income: NT$132.7m (up NT$189.5m from 3Q 2021). Profit margin: 38% (up from net loss in 3Q 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Board Change • Nov 16
Less than half of directors are independent There are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). Chairwoman of the Board Rebecca Lee is the most experienced director on the board, commencing their role in 2020. Independent Director Chih-Ming Lin was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Nov 13
Third quarter 2022 earnings released: EPS: NT$0.42 (vs NT$0.18 loss in 3Q 2021) Third quarter 2022 results: EPS: NT$0.42 (up from NT$0.18 loss in 3Q 2021). Revenue: NT$348.1m (down 8.2% from 3Q 2021). Net income: NT$132.7m (up NT$189.5m from 3Q 2021). Profit margin: 38% (up from net loss in 3Q 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 07
Second quarter 2022 earnings released: NT$0.005 loss per share (vs NT$0.051 profit in 2Q 2021) Second quarter 2022 results: NT$0.005 loss per share (down from NT$0.051 profit in 2Q 2021). Revenue: NT$356.1m (down 32% from 2Q 2021). Net loss: NT$1.53m (down 109% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Tillkännagivande • Aug 06
Savior Lifetec Corporation Appoints as Xu Fang Zhen Head of Internal Audit Savior Lifetec Corporation appointed as Xu Fang Zhen Head of Internal Audit. Name, title, and resume of the new position holder: XU FANG ZHEN, internal audit officer /Deputy Audit Manager of UNISON COMPANY LTD. Effective date is August 5, 2022. Tillkännagivande • Jun 02
Savior Lifetec Corporation Announces Appointment of Cheng, Chin-Hwa as Member of the Audit Committee Savior Lifetec Corporation announced changes in the members of the audit committee with appointment of Cheng, Chin-Hwa as new member . Date of change is June 1 2022. Resume of the new position holder: Independent director of Chongdah health co. Ltd. Reported Earnings • May 08
First quarter 2022 earnings released: NT$0.17 loss per share (vs NT$0.25 profit in 1Q 2021) First quarter 2022 results: NT$0.17 loss per share (down from NT$0.25 profit in 1Q 2021). Revenue: NT$307.3m (down 39% from 1Q 2021). Net loss: NT$54.0m (down 168% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent There are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). Chairwoman of the Board Rebecca Lee is the most experienced director on the board, commencing their role in 2020. Independent Director Chih-Ming Lin was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Tillkännagivande • Apr 16
Savior Lifetec Corporation Approves the Appointment of Cheng, Chin-Hwa as Members of the Compensation Committee Savior Lifetec Corporation approved the appointment of Cheng, Chin-Hwa as members of the compensation Committee. Resume of the new position holder: Independent director of Chongdah health co. Ltd. Effective date of the new member is April 15, 2022. Reported Earnings • Mar 13
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: NT$0.03 (down from NT$0.84 in FY 2020). Revenue: NT$1.74b (down 4.6% from FY 2020). Net income: NT$9.96m (down 96% from FY 2020). Profit margin: 0.6% (down from 14% in FY 2020). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 25%. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Tillkännagivande • Jan 30
Savior Lifetec Corporation Announces Change the Representative of Its Legal Person Director, Effective on February 1, 2022 Savior Lifetec Corporation announced change the representative of the company's legal person director. Name of the previous position holder: LIN, MIN-SHIANG. Resume of the previous position holder: HUA ENG WIRE & CABLE CO., LTD. the representative of the director. Name of the new position holder: Wu Chia-Yu. Resume of the new position holder: HUA ENG WIRE & CABLE CO., LTD. Accounting Supervisor. Reason for the change: Change of representative of corporate director. On January 28, 2022, the company received a notice from the legal director Hua Eng Wire and Cable Co. Ltd. to change the representative, and it took effect on February 1, 2022. Reported Earnings • Nov 07
Third quarter 2021 earnings released: NT$0.18 loss per share (vs NT$0.14 profit in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: NT$379.0m (down 12% from 3Q 2020). Net loss: NT$56.8m (down 226% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 09
Second quarter 2021 earnings released: EPS NT$0.05 (vs NT$0.084 in 2Q 2020) The company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: NT$523.6m (up 30% from 2Q 2020). Net income: NT$16.2m (down 30% from 2Q 2020). Profit margin: 3.1% (down from 5.7% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improved over the past week After last week's 16% share price gain to NT$34.00, the stock trades at a trailing P/E ratio of 38.5x. Average forward P/E is 19x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 22% over the past three years. Reported Earnings • Mar 20
Full year 2020 earnings released: EPS NT$0.88 (vs NT$0.019 loss in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$1.83b (up 39% from FY 2019). Net income: NT$250.9m (up NT$255.9m from FY 2019). Profit margin: 14% (up from net loss in FY 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Jan 15
New 90-day low: NT$29.85 The company is down 6.0% from its price of NT$31.85 on 16 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 19% over the same period. Is New 90 Day High Low • Dec 25
New 90-day high: NT$35.75 The company is up 10.0% from its price of NT$32.40 on 25 September 2020. The Taiwanese market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 13% over the same period. Reported Earnings • Nov 08
Third quarter 2020 earnings released: EPS NT$0.15 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$429.3m (up 26% from 3Q 2019). Net income: NT$45.0m (up NT$43.1m from 3Q 2019). Profit margin: 11% (up from 0.6% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Oct 22
New 90-day low: NT$31.20 The company is down 7.0% from its price of NT$33.50 on 24 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.